Most pancreatic tumors are surrounded by a thick, nearly impenetrable wall of fibrosis— scar tissue—that makes it hard for drugs to access and destroy the cancer cells. Researchers at the Salk ...

Though there are four histone deacetylase (HDAC) inhibitors that are FDA approved to treat some forms of lymphoma, there’s less evidence for their efficacy in solid tumors. Now, new findings in mice ...

Scientists at the University of Miami have developed a genetically engineered cell line to show that HDAC inhibitors could potentially target and stamp out “stubborn reservoirs” of breast and ovarian ...

Researchers have shown how estrogen receptor-positive breast cancer tumors become resistant to tamoxifen, the only approved hormonal therapy for premenopausal patients with this type of breast cancer.

HDAC inhibitors work by inducing cell cycle arrest, promoting differentiation, and triggering apoptosis in various human cancer cell lines. By inhibiting histone deacetylase, they increase acetylation ...

MIAMI, October 3, 2016 -- A group of researchers, led by scientists at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, has shown that histone deacetylase ...

In their bid to find the best combination of therapies to treat anaplastic thyroid cancer (ATC), researchers on Mayo Clinic's Florida campus demonstrated that all histone deacetylase (HDAC) inhibitors ...

SAN ANTONIO -- Adding a histone deacetylase (HDAC) inhibitor to standard endocrine therapy led to a modest but statistically significant improvement in progression-free survival (PFS) in advanced ...

A group of researchers, led by scientists at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, has shown that histone deacetylase (HDAC) inhibitors have the ...

Survival in advanced hormone receptor (HR)-positive breast cancer did not improve with the addition of a histone deacetylase (HDAC) inhibitor to standard endocrine therapy, according to a randomized ...